Myeloid Leukemia

146 Mokany et al.
21. It is possible to set looser acceptance criteria if the investigator realizes that this
limits the discrimination of the assay, for example a ratio between 0.33 and 3
indicates that the assay cannot discriminate differences less than threefold.
References
1. Grimwade, D. and Enver, T. (2004) Acute promyelocytic leukemia: where does it
stem from? Leukemia 18(3), 375–384.
2. Mistry, A. R., Pedersen, E. W., Solomon, E., and Grimwade, D. (2003) The molecular
pathogenesis of acute promyelocytic leukaemia: implications for the clinical
management of the disease. Blood Reviews 17(2), 71–91.
3. Degos, L. and Wang, Z. Y. (2001) All trans retinoic acid in acute promyelocytic
leukemia. Oncogene 20, 7140–7145.
4. Grimwade, D. and Enver, T. (2002) The significance of minimal residual disease
in patients with t(15;17). Best Pract. Res. Clin. Haematol. 15(1), 137–158.
5. Lo Coco, F., Diverio, D., Avvisati, G., et al. (1999) Therapy of molecular relapse
in acute promyelocytic leukemia. Blood 94, 2225–2229.
6. Grimwade, D. and Lo Coco, F. (2002) Acute promyelocytic leukemia: a model
for the role of molecular diagnosis and residual disease monitoring in directing
treatment approach in acute myeloid leukemia. Leukemia 16, 1959–1973.
7. Applegate, T. L., Iland, H. J., Mokany, E., and Todd, A. V. (2002) Diagnosis and
molecular monitoring of acute promyelocytic leukemia using DzyNA reverse transcription-PCR
to Quantify PML-RARα fusion transcripts. Clin. Chem. 48(8),
1338–1343.
8. Applegate, T.L., Iland, H. J., Mokany, E., and Todd, A. V. (2002) Molecular monitoring
of acute promyelocytic leukemia by DzyNA reverse transcriptase. Clinical
Chemistry 48, 1858–1860.9. Jurcic, J. G. (2003) Monitoring PML-RARalpha in
acute promyelocytic leukemia. Curr. Oncol. Rep. 5(5), 391–398.
9. Jurcic, J. G. (2003) Monitoring PML-RARalpha in acute promyelocytic leukemia.
Curr. Oncol. Rep. 5, 391–398.
10. Gu, B. W., Hu, J., and Xu, L. (2001) Feasibility and clinical significance of realtime
quantitative RT-PCR assay of PML-RARalpha fusion transcript in patients
with acute promyelocytic leukemia. Hematol. J. 2(5), 330–340.
11. Slack, J. L., Bi, W., and Livak, K. J. (2001) Pre-clinical validation of a novel,
highly sensitive assay to detect PML-RARalpha mRNA using real-time reversetranscription
polymerase chain reaction. J. Mol. Diagn. 3(4), 141–149.
12. Gabert, J. and Beillard, E. (2003) Standardization and quality control studies of
’real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion
gene transcripts for residual disease detection in leukemia—a Europe Against
Cancer program. Leukemia 17(12), 2318–2357.
13. Larsen, R. (2003) BD QZyme Assays for Quantitative PCR. Clontechniques
XVIII(4), 2–3.
14. Larsen, R., Sheng, D., and Tan, M. (2004) Successful Duplexing of Randomly
Selected BD QZyme qPCR Assays. Clontechniques XIX, 10–11.